The mission of our clinical research is to foster discoveries in the novel therapies of inflammatory bowel diseases, gastrointestinal and pancreatic cancer, hepatitis, and other gastrointestinal disorders. Our doctors are committed to providing the best care and management of diseases while testing cutting-edge therapies.

Back to full list of clinical trials

Ongoing clinical trials for gastroparesis: Actively recruiting


Condition:

Gastroparesis

Study title:

Non-Invasive Characterization of Gastric Motility Using MRI

Description of study:

This research study is being done to help us better understand functional dyspepsia, which is upper abdominal pain or discomfort, frequently related to meals.

Basic eligibility criteria:

Women cannot be pregnant or plan to become pregnant during the study, no previous gastrointestinal surgery, electrolyte disturbances, kidney dysfunction, or iron overload disorders, no metal or magnetic implants (such as metallic clips in the brain or cardiac pacemakers).

Principal Investigator:

Braden Kuo, MD

Contact:

Shahar Castel; 617-726-0196


Condition:

Gastroparesis

Study title:

A Pilot Study on the Efficacy and Safety of Olanzapine in Improving Symptoms and Gastric Motility in Gastroparesis

Description of study:

Aim 1: Investigate the efficacy and safety of olanzapine in the treatment of non-diabetic gastroparesis.
Aim 2: Determine whether olanzapine has prokinetic effects on gastric emptying in gastroparesis.
Aim 3: Examine the effects of olanzapine on neurohumoral regulation of eating and appetite.

Basic eligibility criteria:

This is a pilot study of 20 consecutive subjects ages 18 – 65 with documented delayed gastric emptying within the past 2 years and history of nausea, vomiting, bloating, anorexia, early satiation, post-prandial fullness, and weight loss for at least 6 months without structural or organic cause will be enrolled.

Principal Investigator:

Braden Kuo, MD

Contact:

Shahar Castel; 617-726-0196


Ongoing clinical trials for gastroparesis: No longer recruiting


Study title:

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase II Study to Evaluate the Safety and Efficacy and Dose Response of 28 Days of Once-Daily Dosing of the Oral Motilin Receptor Agonist GSK962040, in Type I and II Diabetic Male and Female Subjects with Gastroparesis

Description of study:

The purpose of this research study is to test an experimental drug called GSK962040. The researchers want to see if the drug can improve the time of stomach emptying (food and drink emptying from the stomach) in people with diabetes. These people also have a stomach condition called gastroparesis, which means partial paralysis of the stomach. We also want to see if the drug will cause side effects.

Principal Investigator:

Braden Kuo, MD